Abstract
Aims: Levodopa‐carbidopa intestinal gel (LCIG) provides continuous levodopa‐carbidopa delivery through intrajejunal infusion. This study characterized the population pharmacokinetics of levodopa following a 16 h jejunal infusion of LCIG or frequent oral administration of levodopa‐carbidopa tablets (LC‐oral) in subjects with advanced Parkinson's disease (PD).Methods: A non‐linear mixed‐effects model of levodopa pharmacokinetics was developed using serial plasma concentrations from an LCIG phase 1 study and a phase 3 double‐blind, double‐dummy study of the efficacy and safety of LCIG compared with LC‐oral in advanced PD patients (n = 68 for model development; 45 on LCIG and 23 on LC‐oral). The final model was internally evaluated using stochastic simulations and bootstrap and externally evaluated using sparse pharmacokinetic data from 311 subjects treated in a long term safety study of LCIG.Results: The final model was a two compartment model with a transit compartment for absorption, first order elimination, bioavailability for LCIG (97%; confidence interval = 95% to 98%) relative to LC‐oral, different first order transit absorption rate constants (LCIG = 9.2 h–1 vs. LC‐oral = 2.4 h–1; corresponding mean absorption time of 7 min for LCIG vs. 25 min for LC‐oral) and different residual (intra‐subject) variability for LCIG (15% proportional error, 0.3 μg ml−1 additive error) vs. LC‐oral (29% proportional error, 0.59 μg ml−1 additive error). Estimated oral clearance and steady‐state volume of distribution for levodopa were 24.8 l h−1 and 131 l, respectively.Conclusions: LCIG administration results in faster absorption, comparable levodopa bioavailability and significantly reduced intra‐subject variability in levodopa concentrations relative to LC‐oral administration.
Funding Information
  • AbbVie

This publication has 28 references indexed in Scilit: